429 related articles for article (PubMed ID: 25722318)
1. Targeting the androgen receptor in prostate and breast cancer: several new agents in development.
Proverbs-Singh T; Feldman JL; Morris MJ; Autio KA; Traina TA
Endocr Relat Cancer; 2015 Jun; 22(3):R87-R106. PubMed ID: 25722318
[TBL] [Abstract][Full Text] [Related]
2. Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance.
Lim SC; Jansson PJ; Assinder SJ; Maleki S; Richardson DR; Kovacevic Z
FASEB J; 2020 Sep; 34(9):11511-11528. PubMed ID: 32713076
[TBL] [Abstract][Full Text] [Related]
3. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer.
Guo C; Yeh S; Niu Y; Li G; Zheng J; Li L; Chang C
Cancer Lett; 2017 Jul; 397():133-143. PubMed ID: 28323036
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of androgen receptor variants in hormone-sensitive prostate cancer xenografts, castration-resistant sublines, and patient specimens according to the treatment sequence.
Honda M; Kimura T; Kamata Y; Tashiro K; Kimura S; Koike Y; Sato S; Yorozu T; Furusato B; Takahashi H; Kiyota H; Egawa S
Prostate; 2019 Jun; 79(9):1043-1052. PubMed ID: 30998834
[TBL] [Abstract][Full Text] [Related]
5. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
Nguyen MM; Wang Z
Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
[TBL] [Abstract][Full Text] [Related]
6. IL-1-conferred gene expression pattern in ERα
Nawas AF; Kanchwala M; Thomas-Jardin SE; Dahl H; Daescu K; Bautista M; Anunobi V; Wong A; Meade R; Mistry R; Ghatwai N; Bayerl F; Xing C; Delk NA
BMC Cancer; 2020 Jan; 20(1):46. PubMed ID: 31959131
[TBL] [Abstract][Full Text] [Related]
7. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
Isaacsson Velho P; Carducci MA
Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
[TBL] [Abstract][Full Text] [Related]
8. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
9. Androgens and estrogens stimulate ribosome biogenesis in prostate and breast cancer cells in receptor dependent manner.
Ray S; Johnston R; Campbell DC; Nugent S; McDade SS; Waugh D; Panov KI
Gene; 2013 Aug; 526(1):46-53. PubMed ID: 23608168
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous targeting of androgen receptor (AR) and MAPK-interacting kinases (MNKs) by novel retinamides inhibits growth of human prostate cancer cell lines.
Ramamurthy VP; Ramalingam S; Gediya L; Kwegyir-Afful AK; Njar VC
Oncotarget; 2015 Feb; 6(5):3195-210. PubMed ID: 25605250
[TBL] [Abstract][Full Text] [Related]
12. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance.
Crona DJ; Milowsky MI; Whang YE
Clin Pharmacol Ther; 2015 Dec; 98(6):582-9. PubMed ID: 26331358
[TBL] [Abstract][Full Text] [Related]
13. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
Centenera MM; Selth LA; Ebrahimie E; Butler LM; Tilley WD
Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29530945
[TBL] [Abstract][Full Text] [Related]
14. New Therapeutic Target for Prostate Cancer.
Cancer Discov; 2016 Jun; 6(6):OF6. PubMed ID: 27091858
[TBL] [Abstract][Full Text] [Related]
15. Targeting the androgen receptor and overcoming resistance in prostate cancer.
Einstein DJ; Arai S; Balk SP
Curr Opin Oncol; 2019 May; 31(3):175-182. PubMed ID: 30893145
[TBL] [Abstract][Full Text] [Related]
16. Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling.
El-Sayed IY; Daher A; Destouches D; Firlej V; Kostallari E; Maillé P; Huet E; Haidar-Ahmad N; Jenster G; de la Taille A; Abou Merhi R; Terry S; Vacherot F
Cancer Lett; 2017 Dec; 410():100-111. PubMed ID: 28935391
[TBL] [Abstract][Full Text] [Related]
17. Advances in androgen receptor targeted therapy for prostate cancer.
Ahmed A; Ali S; Sarkar FH
J Cell Physiol; 2014 Mar; 229(3):271-6. PubMed ID: 24037862
[TBL] [Abstract][Full Text] [Related]
18. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
[TBL] [Abstract][Full Text] [Related]
19. Targeting androgen receptor (AR) with antiandrogen Enzalutamide increases prostate cancer cell invasion yet decreases bladder cancer cell invasion via differentially altering the AR/circRNA-ARC1/miR-125b-2-3p or miR-4736/PPARγ/MMP-9 signals.
Deng G; Wang R; Sun Y; Huang CP; Yeh S; You B; Feng C; Li G; Ma S; Chang C
Cell Death Differ; 2021 Jul; 28(7):2145-2159. PubMed ID: 34127806
[TBL] [Abstract][Full Text] [Related]
20. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]